Compare · CLPT vs RMD
CLPT vs RMD
Side-by-side comparison of ClearPoint Neuro Inc. (CLPT) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLPT and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $28.44B, about 73.6x CLPT ($386.6M).
- Over the past year, CLPT is up 0.8% and RMD is down 22.9% - CLPT leads by 23.6 points.
- CLPT has been more active in the news (18 items in the past 4 weeks vs 6 for RMD).
- RMD has more recent analyst coverage (25 ratings vs 5 for CLPT).
- Company
- ClearPoint Neuro Inc.
- ResMed Inc.
- Price
- $13.42+4.19%
- $193.72-1.17%
- Market cap
- $386.6M
- $28.44B
- 1M return
- +15.09%
- -6.32%
- 1Y return
- +0.75%
- -22.86%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 18
- 6
- Recent ratings
- 5
- 25
ClearPoint Neuro Inc.
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system, a neuro-navigation system designed for instruments or devices designed to treat various neurological diseases and conditions, as well as for performing biopsies. In addition, the company's product pipeline includes ClearTrace system, a product candidate designed to perform minimally invasive surgical procedures in the heart. It has license and collaboration agreements with The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Microsystems, LLC, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Irvine, California.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest CLPT
- Director Richards Timothy T. sold $65,901 worth of shares (5,415 units at $12.17), decreasing direct ownership by 6% to 87,198 units (SEC Form 4)
- ClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global Footprint
- SEC Form 4 filed by Director Johnson B Kristine
- SEC Form 4 filed by Director Liau Linda M.
- SEC Form 4 filed by Director Fallon Lynnette C
- SEC Form 4 filed by Director Fletcher R John
- Director Klein Matthew B. sold $185,440 worth of shares (16,000 units at $11.59), decreasing direct ownership by 25% to 46,935 units (SEC Form 4)
- SEC Form 4 filed by Director Richards Timothy T.
- Director Fallon Lynnette C converted options into 12,417 shares and sold $56,714 worth of shares (5,091 units at $11.14) as part of a pre-agreed trading plan, increasing direct ownership by 18% to 48,227 units (SEC Form 4)
- Director Klein Matthew B. converted options into 12,417 shares, increasing direct ownership by 25% to 62,935 units (SEC Form 4)
Latest RMD
- Global General Counsel Rider Michael J covered exercise/tax liability with 269 units of ResMed Common Stock, decreasing direct ownership by 3% to 9,488 units (SEC Form 4) (tax withholding)
- Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million
- Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
- SEC Form SD filed by ResMed Inc.
- Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
- Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care
- Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,037,233 worth of ResMed Common Stock (4,991 units at $207.82) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 3 filed by new insider Bloomer Aaron
- SEC Form 4 filed by Chief Financial Officer Sandercock Brett
- SEC Form 8-K filed by ResMed Inc.